Lexaria is planning to launch new human and animal studies to examine whether DehydraTECH processing can make GLP-1 drugs such as semaglutide even better. Lexaria's heavily-patented DehydraTECH drug delivery technology might improve bioavailability, lower costs, and enhance tolerability, weight-loss po...
The Canadian Pharmacists Association says protecting Canadian drug supplies from mass exportation to the U.S. market remains a priority in light of B.C.'s recent move to limit sales of the diabetes drug Ozempic, which has been hyped as a weight-loss treatment. Prescrip...
Weight loss drug reduces sleep apnoea severity by 62% 26 June 2024 Tirzepatide demonstrated a mean reduction of up to 62.8% on the apnoea-hypopnea index (AHI) compared to placebo in the SURMOUNT-OSA Phase III clinical trials. The drug was tested for the treatment of moderate-to-severe obst...
pancreas. SGLT-2 drugs significantly manage cardiovascular risk factors, including blood pressure, cardiac function, and antiinflammatory activity. SGLT-2 inhibitors are effective at lowering hemoglobin A1c levels and improving weight loss. They include a low risk of hypoglycemia and are usually well ...
unexplained weight loss, cramps of the calf muscles, tingling and numbness in the limbs, visual impairment, itching of the skin and mucous genitals, severe weakness and fatigue, poor wound healing and recurrent urinary tract infections. If a person discovers these symptoms, you need to see a do...
Its treatments Ozempic and Wegovy are now household names, thanks to their potent weight loss effects and surging use. Yet Novo faces competition from Eli Lilly, which has an Ozempic competitor in Mounjaro, and smaller drugmakers looking to replicate Novo’s and Lilly’s success in obesity. ...
France's drug regulator and one of its leading drug companies, Servier, will stand trial as legal persons over the marketing of the antidiabetes and weight loss drug benfluorex (marketed in France as Mediator), which is believed to have killed between 500 and 2300 people before being pulled...
DIABETES DRUG TESTED FOR WEIGHT LOSS COULD BE GAME CHANGER That does not include if someone needs tovisit the emergency room, be admitted to the hospital or even use home health services. Those services can amount to a combined $590 for diabetes and $320 for chronic complications. ...
increased satiety—the two main mechanisms that impact eating behaviour. Qnexa, an investigational drug, is being developed to address weight loss. In phase 2 and 3 clinical data to date, Qnexa has demonstrated significant weight loss, glycemic control, and improvement in cardiovascular risk factors...
For years, doctors had relatively few options to offer the many patients for whom diet and exercise didn’t work—things like the type 2diabetesdrugmetformin, which can cause amodestamount of weight loss, andbariatric surgery, which works well but is unpopular among patients. And then came Oze...